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Abstract
Aims: Preoperative short-course radiotherapy (SCRT) is an important treatment option for rectal cancer. The length of time between completing SCRT and
surgery may inﬂuence postoperative outcomes, but the evidence available to determine the optimal interval is limited and often conﬂicting.
Materials and methods: Information was extracted from a colorectal cancer data repository (CORECT-R) on all surgically treated rectal cancer patients who
received SCRT in the English National Health Service between April 2009 and December 2014. The time from radiotherapy to surgery was described across the
population. Thirty-day postoperative mortality, returns to theatre, length of stay and 1-year survival were investigated in relation to the interval between
radiotherapy and surgery.
Results: Within the cohort of 3469 patients, the time to surgery was 0e7 days for 76% of patients, 8e14 days for 19% of patients and 15e27 days for 5% of
patients. There was a clear variation in relation to different patient characteristics. There was, however, no evidence of differences in postoperative outcomes in
relation to interval length.
Conclusions: This study suggests that the time interval between SCRT and surgery does not inﬂuence postoperative outcomes up to a year after surgery. The
study provides population-level, real-world evidence to complement that from clinical trials.
 2019 The Royal College of Radiologists. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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Neoadjuvant short-course radiotherapy (SCRT) is an
effective treatment for rectal cancer. Randomised trials have
shown that although it reduces the risk of locally recurrent
disease, it does not inﬂuence survival [1e4]. Furthermore, it
may be associated with an increased risk of treatment-
related morbidity [5]. Therefore, in routine practice, the
potential beneﬁts of the treatment must be balanced
against its risks. In the UK, patients who have tumours thatAuthor for correspondence: B.A. Levick, Leeds Institute for Data Ana-
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j.clon.2019.08.008are neither low risk (T1-3aN0) nor high risk (circumferen-
tial resection margin (CRM) threatened) are recommended
to be considered for SCRT, usually delivered as 25 Gy in ﬁve
fractions with surgery undertaken immediately after the
completion of radiotherapy [6e8]. The evidence base as to
how long the ‘immediate’ time period should be is con-
ﬂicting. Consequently, recommendations regarding the
timing of surgery after the completion of radiotherapy vary
widely internationally.
Within Europe, individual guidelines also vary, but
generally state that surgery should be undertaken within
2e4 working days [2,4,7e12] (Figure 1A). This recommen-
dation arose from a subset analysis of the Dutch total
mesorectal excision (TME) trial, which reported an increase
in postoperative mortality in people over 75 years of ageis is an open access article under the CC BY license (http://creativecommons.
Course Radiotherapy in Rectal Cancer and its Impact on Postoperative
lth Service, 2009e2014, Clinical Oncology, https://doi.org/10.1016/
Fig 1. (A) Distribution of the length of the interval before receiving surgery in short-course radiotherapy (SCRT) patients across the English
National Health Service and current recommendations for interval length; (B) summary of current evidence of differences in outcomes with
different interval lengths.
B.A. Levick et al. / Clinical Oncology xxx (xxxx) xxx2when the interval was 4e7 days compared with 0e3 days
[10]. Despite an accompanying population-based study
being unable to replicate the ﬁnding, these data have been
used to support a policy of rapid surgery after SCRT.
The recent Stockholm III study randomised patients to
three arms: SCRT (5  5 Gy) with surgery within 0e7 days,
SCRT (5  5 Gy) with surgery within 28e56 days or long-
course radiotherapy (25  2 Gy) and surgery within
28e56 days. It found that there were similar oncological
results and postoperative mortality across all these groups,Please cite this article as: Levick BA et al., Time to Surgery Following Short-
Outcomes. A Population-Based Study Across the English National Hea
j.clon.2019.08.008but postoperative complications were signiﬁcantly reduced
in the SCRT group with a longer interval (28e56 days)
before surgery. They concluded that delaying surgery may,
therefore, be a useful approach, with longer intervals being
advantageous [13].
In England, little is known about the intervals adopted
between SCRT and surgery or their impact on patient out-
comes. Patterns of use and outcomes of both SCRT and
surgery can, however, be determined from linked, routinely
collected, population-based National Health Service (NHS)Course Radiotherapy in Rectal Cancer and its Impact on Postoperative
lth Service, 2009e2014, Clinical Oncology, https://doi.org/10.1016/
B.A. Levick et al. / Clinical Oncology xxx (xxxx) xxx 3datasets [14]. Therefore, the aim of this study was to use
these population-based data to examine the variation in
SCRT to surgery intervals across the English NHS and to
relate this to postoperative outcomes up to a year after
surgery. It also aimed to determine if the ﬁndings of the
Dutch TME trial [2,10] were replicated in a population-
based ‘real-world’ dataset.Materials and Methods
Data were obtained from the UK Colorectal Cancer In-
telligence Hub’s colorectal cancer data repository (CORECT-
R), within which the National Cancer Registry and Analysis
Services data are linked to many other datasets, including
Hospital Episode Statistics and the National Radiotherapy
Dataset.
Informationwas extracted on all individuals in the English
NHS with a primary diagnosis of rectal cancer (ICD-10 C20)
[15] made between 1 April 2009 and 31 December 2014,
who received SCRT followed by a major resection. Patients
who had records of either ﬁve (25 Gy in ﬁve fractions) or four
(20 Gy in four fractions, delivered as an equivalent regimen at
one centre) attendances for radiotherapy and subsequently
underwent surgery in 27 days from their last attendance
for radiotherapy were deﬁned as receiving SCRT.
Those who had an interval >27 days were excluded as it
was assumed that most of these individuals were probably
receiving SCRT with an intended delay. This treatment is
increasingly used as an alternative to long-course neo-
adjuvant chemoradiotherapy in individuals with more
advanced tumours, where the risk of involved surgical
margins is high, but concern exists about the patient’s
ability to tolerate chemoradiotherapy (due to frailty or co-
morbidity). In this context, the delay between radiotherapy
and surgery is planned to allow the tumour to be down-
staged before resection. Unfortunately, this precluded direct
comparison of the results of these observational data with
those of two arms of the Stockholm III study (SCRT with
delay and long-course radiotherapy) as the inclusion
criteria of the trial limited their population to those who
were eligible for SCRT with more immediate surgery.
To enable an investigation of the impact of interval
length between SCRT and surgery, the population was split
into a number of groups. First, based on inspection of the
time between SCRT and surgery across this cohort
(Figure 1A), as well as clinical advice on typical working
practices in English hospitals, individuals were grouped into
categories of those with intervals of 0e7, 8e14 or 15e27
days. In addition, in order to make comparisons with the
randomised trials that investigated interval length and
mortality [2,10], individuals were also subdivided into 0e3,
4e7, 8e14 and 15e27 day categories.
Information on variation in interval length in relation to
the characteristics of the population and other relevant
features were extracted from the linked datasets. These
included comorbidity, which was scored using the Charlson
index [16], and categorised as a score of 0, 1, 2 or 3. Op-
erations were classiﬁed from OPCS4 codes using anPlease cite this article as: Levick BA et al., Time to Surgery Following Short-
Outcomes. A Population-Based Study Across the English National Hea
j.clon.2019.08.008algorithm deﬁned previously [17] and consisted primarily
of anterior resection, abdominoperineal excision or Hart-
mann’s procedure. Tumour stage at diagnosis was taken
from registry data. The patient’s socioeconomic deprivation
was categorised into groups using quintiles of the income
domain of the English Index of Multiple Deprivation,
derived from the patient’s postcode at the time of diagnosis
[18]. The patient’s age at diagnosis was categorised as 61,
61e70, 71e80 or 81 years. Again, to enable comparisons
with the previous study, a second grouping of75 and< 75
years was created.
Postoperative outcomes included 30-day mortality, 1-
year postoperative survival, rates of return to theatre [19]
and length of stay.
The interval lengths experienced by key groups in the
population were described. The median time interval and
interquartile range (IQR) was calculated for each of the
multidisciplinary teams managing rectal cancer in the En-
glish NHS. The rates of each postoperative outcome were
calculated by interval length categories. Small cell counts in
tables were suppressed in order to reduce the risk of
disclosure.
The relationship between interval length and 1-year
survival was assessed using a Cox proportional hazards
model. Associations between interval length and length of
stay were tested using a Poisson regression model. Associ-
ations between interval length and binomial outcomes (30-
day mortality and returns to theatre) were tested using
logistic regression models. In each case, the analysis was
carried out as both univariable and multivariable models
adjusted for gender, Charlson comorbidity score and Index
of Multiple Deprivation quintile, stage of tumour at diag-
nosis and age (excluding independent models in those 75
years and <75 years).
The analysis was conducted using the R statistical
computing environment [20] using the ‘survival’ [21,22],
‘readstata13’ [23] and ‘xlsx’ [24] packages and STATA IC 15
[25].Results
In total, 3469 individuals received SCRT followed by
surgery within 27 days across the whole study period.
This represented 11% of all patients diagnosed with rectal
cancer. Most (76.4%) underwent surgery within 7 days of
ﬁnishing radiotherapy, 18.9% experienced an interval of
8e14 days and 4.7% an interval of 15e27 days (Table 1).
Longer intervals (15e27 days) were more common among
patients over the age of 80 years, those with greater co-
morbidity and in those where the tumour stage was not
recorded.
The distribution of intervals between SCRT and surgery is
shown in Figure 1A. The median interval length across in-
dividual multidisciplinary teams ranged from 1 day [IQR 0.5
days (1e1.5)] to 17 days [IQR 13 days (10e23)].
Although small differences in 30-day and 1-year post-
operative mortality, rates of return to theatre and length of
stay were observed between the interval length groups,Course Radiotherapy in Rectal Cancer and its Impact on Postoperative
lth Service, 2009e2014, Clinical Oncology, https://doi.org/10.1016/
Table 1
Characteristics of the population in relation to the interval between radiotherapy and surgery
Patient characteristics and procedures Length of interval between ﬁnishing short-course radiotherapy and surgery Total
0e7 days 8e14 days 15e27 days
n % n % n %
Total number of patients experiencing each length of interval 2652 76.4 656 18.9 162 4.7 3469
Age <61 years 679 76.9 174 19.7 30 3.4 883
61e70 years 960 78.1 222 18.1 48 3.9 1230
71e80 816 75.4 202 18.7 64 5.9 1082
>80 years 197 71.9 57 20.8 20 7.3 274
Gender Male 1793 76.0 451 19.1 114 4.8 2358
Female 859 77.3 204 18.4 48 4.3 1111
Charlson comorbidity index 0 2198 76.8 547 19.1 118 4.1 2863
1 345 75.8 81 17.8 29 6.4 455
2þ* 109 72.2 27 17.9 15 9.9 151
Index of Multiple Deprivation quintile 1 e least deprived 559 76.2 139 18.9 36 4.9 734
2 640 76.9 148 17.8 44 5.3 832
3 577 78.6 127 17.3 30 4.1 734
4 480 76.1 127 20.1 24 3.8 631
5 e most deprived 396 73.6 114 21.2 28 5.2 538
Stage I 527 73.5 158 22.0 32 4.5 717
II 644 77.3 152 18.3 37 4.4 833
III and IV* 1209 78.8 259 16.9 67 4.4 1535
Unknown 272 70.8 86 22.4 26 6.8 384
Procedure Anterior resection 723 71.7 226 22.4 59 5.9 1008
Abdominoperineal excision 1659 79.0 360 17.1 82 3.9 2101
Hartmann’s and other* 270 75.0 69 19.2 21 5.8 360
* Aggregated to suppress small numbers.
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B.A. Levick et al. / Clinical Oncology xxx (xxxx) xxx 5none of these differences was statistically signiﬁcant
(P> 0.1) (Table 2; Figure 2; Supplementary Figure S1, Tables
S1, S2). This was the case even when the analyses were
stratiﬁed in the same age groups as those used in the
inﬂuential subset analysis of the Dutch TME trial
(Supplementary Tables S3eS5, Figure S2). A comparison of
the interval lengths experienced in this English cohort with
current recommendations in Europe and the results of the
relevant trials are summarised in Figure 1B.Fig 2. Association of interval length with 30-day mortality, 1-year
survival and returns to theatre in short-course radiotherapy (SCRT)
patients. Multivariate models (black solid lines) adjusted for age,
gender, stage, Charlson index and Index of Multiple Deprivation
category.Discussion
This study, carried out in the English NHS, is not able to
provide any evidence of worse postoperative outcomes
with a time to surgery of 4e7 days after SCRT compared
with 0e3 days, irrespective of age. Furthermore, this study
found no evidence of any other effect on outcomes when
the interval to surgery was extended up to 27 days from the
completion of SCRT. This shows the limitations of the Van
den Broek et al. [10] subset analyses as well as the impor-
tance of observing the implementation and conﬁrmation of
trial ﬁndings in a real-world setting. As this is the largest
population-based study to be undertaken investigating the
effect of variations in SCRT to surgery intervals, these data
provide important real-world evidence to help inform
future guidance and so optimise the use of SCRT in the
management of rectal cancer. Guidelines recommending
intervals as short as 3e4 working days based on the Van
den Broek et al. [10] study may, therefore, require revision.
This study also found that in the English NHS, although
most patients operated onwithin 27 days of the completion
of radiotherapy were operated on within 7 days (76.4%),
there was substantial variation in the timing between SCRT
and surgery. To an extent, this is not surprising given the
variation in guidelines and recommendations for interval
lengths [2,4,7e12] (Figure 1A). Previous studies have also
described variation in the radiotherapy regimens used to
treat rectal cancer in the English NHS [14]. Although there is
a relevant National Institute for Health and Care Excellence
guideline in place [6], this persistent variation indicates a
need for greater consensus on radiotherapy use for rectal
cancer in the English NHS.
In contrast to Van den Broek et al. [10], the Stockholm III
trial provided evidence to support longer delays of 28e56
days to surgery; ﬁnding reduced postoperative complica-
tions, albeit with a slightly increased risk of radiotherapy-
related toxicity requiring readmission [13]. Unfortunately,Table 2
Mortality (30 day and 1 year) and returns to surgery after major resect
Length of interval
(days)
30-day postoperative mortality 1-year posto
n % n
0e7 57 2.2 165
8e14 11 1.7 47
15e27* <7 <4% 12
* Small numbers are suppressed.
Please cite this article as: Levick BA et al., Time to Surgery Following Short-
Outcomes. A Population-Based Study Across the English National Hea
j.clon.2019.08.008it was not possible to investigate the effects of these longer
intervals in this cohort as the routine data available did not
allow us to distinguish those who would have met the
eligibility criteria of the Stockholm III trial. This is because
patients whose tumours are threatening, or involving, the
planned resection margins are prescribed SCRT with an
intended delay as an alternative (often due to frailty, poor
performance status or comorbidity) to long-course radio-
therapy or, indeed, long-course chemoradiotherapy, which
is also often used in this setting. Given that these twoion by interval length group
perative mortality Return to theatre within 28 days Total
% n %
6.2 310 11.7 2652
7.2 63 9.6 656
7.3 19 11.7 162
Course Radiotherapy in Rectal Cancer and its Impact on Postoperative
lth Service, 2009e2014, Clinical Oncology, https://doi.org/10.1016/
B.A. Levick et al. / Clinical Oncology xxx (xxxx) xxx6populations pose different surgical risks they are also likely
to experience different outcomes and, as we could not
distinguish between them in the population-based English
rectal cancer data, direct comparisons were precluded. This
is a limitation of the routine data available and further detail
on the planned use of SCRT would be required before any
such comparative analyses could be undertaken.
Deﬁning the optimal interval remains a challenge. Most
current SCRT trial protocols allow up to 7 days from the
completion of SCRT to surgery. The advantages of the 7-day
interval are that there is a limited time for downstaging of
the tumour, which allows decisions regarding stage and risk
stratiﬁcation to be made on the basis of the pathological
stage. Shorter intervals also allow for planned adjuvant
therapy to start sooner, and so reduce the overall treatment
time. In contrast, with longer intervals, a downstaging effect
becomes more likely, and pretreatment restaging imaging
may be required to guide postoperative treatment planning.
Based on the ﬁndings of this study, if ‘immediate’ surgery is
intended it seems reasonable to allow up to 7 days from the
completion of SCRT. This would simplify postoperative
decision-making, allowing plans to be made based on his-
topathological ﬁndings at surgery.
The Stockholm III trial was speciﬁcally designed to
compare oncological outcomes between patients receiving
SCRT with immediate surgery, with delayed surgery or
long-course radiotherapy, and so provides the gold stan-
dard evidence base. As a consequence, SCRT with a 28e56-
day interval is considered to be an acceptable alternative to
SCRT with immediate surgery. As this study was not able to
allocate the population to the trial arms used by the
Stockholm III trial, its value in evaluating whether this
recommendation is applicable in a real-world setting is
limited.
This study has a number of other limitations arising from
its use of linked routine administrative data from the En-
glish NHS. For example, as recurrence data are not routinely
captured it was not possible to assess the effect of interval
length on this outcome. Similarly, the analysis was limited
by a lack of data on important aspects of radiotherapy-
related toxicity, intra- or postoperative morbidity, such as
infection, cardiovascular or respiratory events. Acute pelvic
toxicity associated with radiotherapy and longer term
functional outcomes, as reported by physicians or patients,
are also not routinely collected. Efforts are underway,
however, to increase the scope of the routine data available
and so, in the future, they may support more detailed and
informative observational analyses.
This is, however, the largest population-based observa-
tional study investigating the effect of the interval length
between SCRT and surgery and so provides valuable data to
inform optimal practice. We found no evidence of worsened
mortality outcomes after intervals of 4e7, 8e14 or 15e27
days compared with intervals of 0e3 days. Other studies
have shown the increasing impact of downstaging beyond 7
days. Therefore, the current guidelines and recommended
intervals in trials support an interval length of up to 7 days.
Interval lengths of between 28 and 56 days can also be
used in appropriate populations. This study shows thePlease cite this article as: Levick BA et al., Time to Surgery Following Short-
Outcomes. A Population-Based Study Across the English National Hea
j.clon.2019.08.008importance of investigating the results of trials in a real-
world setting and the dangers of using subset analysis of
randomised trials to inform clinical policy.Conclusions
In conclusion, the study shows that time intervals of 4
days or more between SCRT and surgery are not associated
with worse postoperative outcomes up to a year after sur-
gery for rectal cancer patients.Conﬂict of Interest
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